CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akebia Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akebia Therapeutics Inc
245 First Street
Phone: (617) 871-2098p:617 871-2098 CAMBRIDGE, MA  02142  United States Ticker: AKBAAKBA
Business Summary
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board AdrianAdams 74 12/12/2018 12/12/2018
President, Chief Executive Officer, Director John P.Butler 60 6/24/2024 7/1/2013
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer ErikOstrowski 51 6/24/2024 6/24/2024
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Keryx Biopharmaceuticals 1 Marina Park Drive Boston MA United States

Business Names
Business Name
ACCESS Oncology, Inc.
Accumin Diagnostics, Inc.
AKBA
9 additional Business Names available in full report.

General Information
Number of Employees: 181 (As of 12/31/2024)
Outstanding Shares: 265,365,993 (As of 11/4/2025)
Shareholders: 26
Stock Exchange: NASD
Federal Tax Id: 208756903
Fax Number: (617) 871-2099


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 7, 2025